New study: can a pill stop chemo nausea in advanced breast cancer?
NCT ID NCT07132749
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether the anti-nausea drug NEPA (netupitant/palonosetron) can prevent vomiting and nausea in people with advanced HER2-positive or HER2-low breast cancer who are receiving the drug T-DXd. It will follow 100 participants across multiple hospitals to see how well NEPA works during and after treatment. The goal is to improve comfort and quality of life during cancer therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NEPA (netupitant/palonosetron)
- What this could lead to
- If it works, this could show that NEPA effectively controls nausea and vomiting caused by T-DXd, improving quality of life for advanced breast cancer patients.
- What could go wrong
- This is an observational study, not a randomized trial, so results may be less definitive. It focuses on symptom control, not treating the cancer itself, and the benefit may vary among individuals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Samsung Medical Center
Seoul, Gangnam-gu, 06355, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI tool aims to predict breast cancer drug success, sparing patients unnecessary side effects
- New scan may personalize breast cancer therapy
- Can switching breast cancer drugs improve outcomes? new study watches real-world results.
- New hope for HER2+ breast cancer: Real-World study tests daily pill pyrotinib
- New hope for advanced breast cancer: TQB2930 enters phase 3 trial
- New hope for advanced cancer: experimental drug targets HER2